VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Age : 18-65                                        │ Age : 18-65                                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ MADRS total score of 18 or higher                  │ MADRS total score of 18 or higher                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who responded inadequately (a score of    │ Patients who responded inadequately (a score of    │     100 │
│ \>18 on the MADRS) to first-line antidepressant    │ >18 on the MADRS) to first-line antidepressant     │         │
│ treatment of 4 week duration                       │ treatment of 4 week duration                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of standard antidepressant treatment   │ Current use of standard antidepressant treatment   │     100 │
│ in monotherapy or combination of 2 antidepressants │ in monotherapy or combination of 2 antidepressants │         │
│ : escitalopram (10 - 20mg/d), fluoxetine(20 -      │ : escitalopram (10 - 20mg/d), fluoxetine(20 -      │         │
│ 40mg/d), paroxetine CR(25 - 50mg/d),               │ 40mg/d), paroxetine CR(25 - 50mg/d),               │         │
│ sertraline(100 - 150mg/d), mirtazapine (15 -       │ sertraline(100 - 150mg/d), mirtazapine (15 -       │         │
│ 45mg/d), duloxetine (30 - 60mg/d) or venlafaxine   │ 45mg/d), duloxetine (30 - 60mg/d) or venlafaxine   │         │
│ ER(150-225mg/d)                                    │ ER(150-225mg/d)                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Past history of hypersensitivity to aripiprazole   │ Past history of hypersensitivity to aripiprazole   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Primary diagnosis of MDD with psychotic feature,   │ Primary diagnosis of MDD with psychotic feature,   │     100 │
│ bipolar disorder, schizophrenia, schizoaffective   │ bipolar disorder, schizophrenia, schizoaffective   │         │
│ disorder, other psychotic disorder or anxiety      │ disorder, other psychotic disorder or anxiety      │         │
│ disorder, a history of alcohol/ drug abuse within  │ disorder, a history of alcohol/ drug abuse within  │         │
│ the past 12 months, or a diagnosis of dementia     │ the past 12 months, or a diagnosis of dementia     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically significant current Axis II (DSM-IV-TR) │ Clinically significant current Axis II (DSM-IV-TR) │     100 │
│ diagnosis                                          │ diagnosis                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy or in breast-feeding                     │ Pregnancy or in breast-feeding                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of a serious medical illness including    │ Presence of a serious medical illness including    │     100 │
│ cardiac, hepatic, renal, respiratory,              │ cardiac, hepatic, renal, respiratory,              │         │
│ endocrinologic, neurologic, or hematologic disease │ endocrinologic, neurologic, or hematologic disease │         │
│ or physical disorder judged to significantly       │ or physical disorder judged to significantly       │         │
│ affect central nervous system function             │ affect central nervous system function             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients taking antipsychotics, mood stabilizer or │ Patients taking antipsychotics, mood stabilizer or │     100 │
│ any psychotropic medications besides               │ any psychotropic medications besides               │         │
│ antidepressants, except benzodiazepines or beta    │ antidepressants, except benzodiazepines or beta    │         │
│ blockers or hypnotics                              │ blockers or hypnotics                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with past treatment failures of           │ Patients with past treatment failures of           │     100 │
│ aripiprazole                                       │ aripiprazole                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with major depressive disorder according  │ Patients with major depressive disorder according  │      99 │
│ to DSM-IV criteria that have lasted \>8 weeks      │ to DSM-IV criteria that have lasted >8 weeks       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A significant risk of suicide corroborated by a    │ A significant risk of suicide corroborated by a    │      99 │
│ score of ≥5 on item 10(suicidal thoughts) on the   │ score of =5 on item 10(suicidal thoughts) on the   │         │
│ MADRS scale or by clinical judgment of the         │ MADRS scale or by clinical judgment of the         │         │
│ investigator                                       │ investigator                                       │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                            │   Score │
╞═══════════════════════════════════╪══════════════════════════════════════════╪═════════╡
│ Must have maximum age of 65 Years │ Patients with past treatment failures of │      37 │
│                                   │ aripiprazole                             │         │
├───────────────────────────────────┼──────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ MADRS total score of 18 or higher        │      42 │
╘═══════════════════════════════════╧══════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 91.8
OverAll Ratio: 94.9
